HER2-targeted antibody–drug conjugate (T-DXd) that delivers deruxtecan, a topoisomerase I inhibitor with a membrane-permeable payload enabling bystander effect.
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2 on tumor cells and can induce ADCC; upon internalization a cleavable linker releases deruxtecan (DXd), a membrane‑permeable topoisomerase I inhibitor, leading to DNA damage, replication arrest, apoptosis, and bystander killing of neighboring tumor cells.
YES
DIRECT
ADC binds HER2 via trastuzumab, is internalized, and releases deruxtecan (DXd), a topoisomerase I inhibitor that causes DNA damage and apoptosis; Fc-mediated ADCC also contributes. Membrane-permeable payload enables bystander killing.
HER2-targeted antibody–drug conjugate (T-DXd) that delivers deruxtecan, a topoisomerase I inhibitor with a membrane-permeable payload enabling bystander effect.
HER2-targeted antibody–drug conjugate: trastuzumab binds HER2 on tumor cells and can induce ADCC; upon internalization a cleavable linker releases deruxtecan (DXd), a membrane‑permeable topoisomerase I inhibitor, leading to DNA damage, replication arrest, apoptosis, and bystander killing of neighboring tumor cells.
YES
INDIRECT
After HER2 binding and internalization, the ADC releases deruxtecan, which inhibits DNA topoisomerase I, causing DNA damage, replication arrest, and apoptosis; the membrane-permeable payload can also diffuse to kill nearby cells.
An intravenous, half-life extended bispecific T-cell engager (BiTE) that binds DLL3 on SCLC cells and CD3 on T cells to redirect cytotoxic T-cell killing of DLL3-positive tumor cells.
Half-life–extended bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells, activating and redirecting cytotoxic T cells to mediate lysis of DLL3-expressing tumor cells (e.g., SCLC).
YES
DIRECT
Bispecific T-cell engager binds DLL3 on tumor cells and CD3 on T cells, creating an immune synapse that activates cytotoxic T cells to kill DLL3-positive cells via perforin/granzyme-mediated lysis.
An intravenous, half-life extended bispecific T-cell engager (BiTE) that binds DLL3 on SCLC cells and CD3 on T cells to redirect cytotoxic T-cell killing of DLL3-positive tumor cells.
Half-life–extended bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells, activating and redirecting cytotoxic T cells to mediate lysis of DLL3-expressing tumor cells (e.g., SCLC).
NO
INDIRECT
Tarlatamab binds CD3ε on T cells to activate and redirect them to kill DLL3-expressing tumor cells; CD3+ T cells themselves are not targeted or killed.
A Trop-2-targeted antibody-drug conjugate that delivers SN-38 (irinotecan's active metabolite), a topoisomerase I inhibitor, causing DNA damage and tumor cell death with a potential bystander effect.
A Trop-2-targeted antibody-drug conjugate that binds Trop-2 on tumor cells, is internalized, and releases SN-38 (irinotecan's active metabolite). SN-38 inhibits topoisomerase I by stabilizing Topo I-DNA complexes, leading to DNA breaks, inhibition of replication, and apoptosis, with a potential bystander killing effect.
YES
DIRECT
The ADC binds TROP-2 on tumor cells, is internalized, and releases SN-38, a topoisomerase I inhibitor, causing DNA damage and apoptosis (with potential bystander killing).